Identification of the G994 → T missense mutation in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men

Metabolism: Clinical and Experimental

Volumn 47, Issue 2, 1998, Pages 177-181

  Yamada, Yoshiji ^a   Ichihara, Sahoko ^b   Fujimura, Takaharu ^b   Yokota, Mitsuhiro ^b  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A;

AMINO ACID SUBSTITUTION; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME ACTIVATION; ENZYME ANALYSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; JAPAN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PHOSPHOLIPID SYNTHESIS; PRIORITY JOURNAL; THROMBOSIS; ADULT; AGED; ARTERIOSCLEROSIS; EXON; GENETICS; METABOLISM; MIDDLE AGED; MUTATION; RISK FACTOR;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; ARTERIOSCLEROSIS; CORONARY DISEASE; EXONS; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MUTATION; PHOSPHOLIPASES A; RISK FACTORS;

EID: 0031989324     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(98)90216-5     Document Type: Article

References (32)

1. Marenberg ME, Risch N, Berkman LF, et al: Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 330:1041-1046, 1994
2. Zimmerman GA, Prescott SM, McIntyre TM: Platelet-activating factor: A fluid-phase and cell-associated mediator of inflammation, in Gallin JI, Goldstein IM, Snyderman R (eds): Inflammation: Basic Principles and Clinical Correlates. New York, NY, Raven, 1992, pp 149-176
3. Honda Z, Nakamura M, Miki I, et al: Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung. Nature 349:342-346, 1991
4. Mueller HW, Haught CA, McNatt JM, et al: Measurement of platelet-activating factor in a canine model of coronary thrombosis and in endarterectomy samples from patients with advanced coronary artery disease. Circ Res 77:54-63, 1995
5. Patel KD, Zimmerman GA, Prescott SM, et al: Novel leukocyte agonists are released by endothelial cells exposed to peroxide. J Biol Chem 267:15168-15175, 1992
6. Smiley PL, Stremler KE, Prescott SM, et al: Oxidatively fragmented phosphatidylcholines activate human neutrophils through the receptor for platelet-activating factor. J Biol Chem 266:11104-11110, 1991
7. Heery JM, Kozak M, Stafforini DM, et al: Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J Clin Invest 96:2322-2330, 1995
8. Stafforini DM, Prescott SM, McIntyre TM: Human platelet-activating factor acetylhydrolase: Purification and properties. J Biol Chem 262:4223-4230, 1987
9. Stafforini DM, McIntyre TM, Carter ME, et al: Human plasma platelet-activating factor acetylhydrolase: Association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem 262:4215-4222, 1987
10. Stremler KE, Stafforini DM, Prescott SM, et al: An oxidized derivative of phosphatidylcholine is a substrate for the platelet-activating factor acetylhydrolase from human plasma. J Biol Chem 264:5331-5334, 1989
11. Stremler KE, Stafforini DM, Prescott SM, et al: Human plasma platelet-activating factor acetylhydrolase: Oxidatively fragmented phospholipids as substrates. J Biol Chem 266:11095-11103, 1991
12. Yamada Y, Stafforini DM, Imaizumi T, et al: Characterization of the platelet-activating factor acetylhydrolase from human plasma by heterologous expression in Xenopus laevis oocytes. Proc Natl Acad Sci USA 91:10320-10324, 1994
13. Stafforini DM, Zimmerman GA, McIntyre TM, et al: The platelet-activating factor acetylhydrolase from human plasma prevents oxidative modification of low-density lipoprotein. Trans Assoc Am Physicians 105:44-63, 1992
14. Watson AD, Navab M, Hama SY, et al: Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 95:774-782, 1995
15. Steinberg D, Parthasarathy S, Carew TE, et al: Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320:915-924, 1989
16. Witztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 88:1785-1792, 1991
17. Tjoelker LW, Wilder C, Eberhardt C, et al: Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 374:549-553, 1995
18. Stafforini DM, Satoh K, Atkinson DL, et al: Platelet-activating factor acetylhydrolase deficiency: A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest 97:2784-2791, 1996
19. Miwa M, Miyake T, Yamanaka T, et al: Characterization of serum platelet-activating factor (PAF) acetylhydrolase: Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Invest 82:1983-1991, 1988
20. Nora JJ, Lortscher RH, Spangler RD, et al: Genetic-epidemiologic study of early-onset ischemic heart disease. Circulation 61:503-508, 1980
21. Guetta V, Cannon RO III: Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation 93:1928-1937, 1996
22. Miyaura S, Maki N, Byrd W, et al: The hormonal regulation of platelet-activating factor acetylhydrolase activity in plasma. Lipids 26:1015-1020, 1991
23. Ross R: The pathogenesis of atheroscleosis: A perspective for the 1990s. Nature 362:801-809, 1993
24. Regnström J, Nilsson J, Tornvall P, et al: Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 339:1183-1186, 1992
25. Brown MS, Goldstein JL: Lipoprotein metabolism in the macrophage: Implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 52:223-261, 1983
26. Stary HC, Chandler AB, Dinsmore RE, et al: A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 15:1512-1531, 1995
27. Imaizumi T, Stafforini DM, Yamada Y, et al: Platelet-activating factor: A mediator for clinicians. J Intern Med 238:5-20, 1995
28. Osterman G, Lang A, Holtz H, et al: The degradation of platelet-activating factor in serum and its discriminative value in atherosclerotic patients. Thromb Res 52:529-540, 1988
29. Satoh K, Yoshida H, Imaizumi T, et al: Platelet-activating factor acetylhydrolase in plasma lipoproteins from patients with ischemic stroke. Stroke 23:1090-1092, 1992
30. Tew DG, Southan C, Rice SQJ, et al: Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins. Arterioscler Thromb Vasc Biol 16:591-599, 1996
31. Steinbrecher UP, Parthasarathy S, Leake DS, et al: Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 81:3883-3887, 1984
32. Steinbrecher UP, Lougheed M, Kwan W-C, et al: Recognition of oxidized low density lipoprotein by the scavenger receptor of macrophages results from derivatization of apolipoprotein B by production of fatty acid peroxidation. J Biol Chem 264:15216-15223, 1989